PREPARATION AND CHARACTERISATION OF CATIONIC SOLID LIPID NANOPARTICLES AS A POTENTIAL DNA DELIVERY SYSTEM

WOS: 00020934590007

The effects of lyophilization and cryoprotectants on solid lipid nanoparticle-DNA systems

WOS: 000423282700020The development of optimized plasmid DNA delivery systems is necessary to deliver genetic material for effective gene therapy. To achieve this aim, a novel SLN: pDNA system was developed and the influence of the lyophilization procedure and the role of cryoprotectants in establishing the system's characteristics and stability were examined. SLNs were prepared by modified microemulsion dilution method. Afterward, a green fluorescent protein expression plasmid was loaded into the SLN system via electrostatic interactions. To examine the effects of cryoprotectants on the lyophilization process, sucrose, mannose, and trehalose were added at different ratios into the dilution medium; Tween 80 was also studied as an outer surfactant without cryoprotectants by incorporating it into the dilution medium. The system was characterized before and after the lyophilization procedure and tested with pDNA-loaded and unloaded SLNs. The compact form of the SLN: pDNA complexes were dissociated with cryoprotectants except %5 sucrose. Redispersing lyophilized SLNs and forming complexes with pDNA in an aseptic environment would be suitable at the application stage.Ege University, TurkeyEge University [09-ECZ-011]We are thankful to the Research Fund of Ege University, Turkey for financial support (Project No: 09-ECZ-011)

Development of novel precirol based cationic solid lipid nanoparticles by microemulsion dilution method as DNA delivery system

European Biotechnology Congress -- SEP 28-OCT 01, 2011 -- Istanbul, TURKEYWOS: 000295310800413European Biotechnol Themat Network Asso

Development of novel cationic solid lipid nanoparticles as gene delivery system: Characterization and transfection ability

European Biotechnology Congress -- SEP 28-OCT 01, 2011 -- Istanbul, TURKEYWOS: 000295310800412European Biotechnol Themat Network Asso

Critical time point for apoptotic cell death in an experimental ischemia/reperfusion model and the effect of N-acetylcystein

WOS: 000405121500004Objective: Kidney transplantation is an important treatment option in end stage renal failure. Tissue death may be an important problem when a kidney is removed from a cadaver and transported to a donor a long distance away. The purpose of this study is to determine the critical time point for apoptotic cell death in a renal ischemia/reperfusion model and determine the effects of N-acetylcystein on apoptosis induced by ischemia injury. Methods: Apoptotic cell death after induced renal ischemia followed by reperfusion, was estimated in a group of Wistar albino rats by immunoflourescence and ELISA techniques. N-acetylcystein, an antioxidant agent, was given to the rats to study the effect on apoptosis. Tissues were examined immunohistochemically at 0, 1 h, 24 h, 5 days and 10 days for detection of apoptotic cells. Results: Our results showed that an ischemia for 60 min followed by reperfusion for 60 min triggered apoptosis. Moreover, N-acetylcystein significantly diminished both the ischemia/reperfusion damage and apoptosis. Conclusion: We anticipate our results would be important for kidney transplantation in estimating the critical time point for apoptosis and administration of N-acetylcystein prior to removal of the organ may be important in delaying the onset of apoptosis

Silencing acpP gene via antisense oligonucleotide-niosome complex in clinical Pseudomonas aeruginosa isolates

Pseudomonas aeruginosa, an opportunistic Gram-negative pathogen, is one of the major causes of nosocomial infections. In addition to its physiological adaptation capacity, it can develop resistance to disinfectants and antibiotics through various mechanisms. Recently, new eradication methods are gaining attention. Therefore, in this study, an LNA-2'-O-methyl hybrid antisense oligonucleotide targeting the acyl carrier protein P (acpP) gene was introduced into P. aeruginosa isolates. The design was determined through sequence analysis and prediction of the secondary structure of mRNA by software. Niosomes were used for enhancing cellular uptake. The control of the binding and transfection ability of the sequence was determined fluorometrically by labeling with 6-Fam. The effects were determined with broth microdilution method and qPCR studies. Eight different formulations were prepared. Among these, one formulation has shown to have ASO complexation ability whose composition was 312 mu l Span 80 + 69.5 mg Cholesterol+ 36.4 mg CTAB+1 ml Chloroform and 5 ml dH(2)O. Thus this formulation was determined as the delivery system for the next stages. Significant gene inhibition was detected at the six isolates. Results of this study suggested that niosomes can be used as a delivery system for cellular uptake of ASO and could eliminate bacterial growth. (C) 2021 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.Scientific and Technological Research Council of Turkey [215S824]The Scientific and Technological Research Council of Turkey by Grant No. 215S824 financially supported this study

Safety Evaluation and Tolerability Overview of Favipiravir in the Management of COVID-19: A Real-Life Experience from Turkey

Introduction: Coronavirus diseases-2019 (COVID-19) have been ongoing for more than two years. Despite the scientific researchconducted in this process, there is still no widely accepted definitive treatment for the disease. For treating COVID-19, using antiviralagents previously used for the treatment of other RNA-virus infections has been seen as a fast way to a solution, and favipiravir is oneof the leading agents. This prospective, multicenter, observational study was designed to investigate the safety of favipiravir in 500patients treated with favipravir for favipravir.Methods: This study was conducted as a multicenter prospective study. Eight different sites from four cities participated, and 500patients were included in the study. Follow-up of laboratory parameters, adverse events (AEs), and amelioration of fever, dyspnea,and cough symptoms of the patients was recorded in a case report form.Results: A total of 475 patients from eight centers completed the study. A total of 401 AEs were reported in 206 (51.4%) patients, whichwere mild-to-moderate in the majority of cases. Serious AEs occurred in 5 patients and death occurred in 4 patients. From the first tothe last measurement, serum alanine aminotransferase levels (31.9±27.7 vs. 47.2±49.7 U/L, p&lt;0.001) increased, whereas C-reactiveprotein (39.9±66.4 vs. 15.2±30.5 mg/L, p&lt;0.001) and creatine kinase (101.7±187.7 vs. 71.9±43.5 U/L, p=0.018) levels decreased. Infollow-up parameters, oxygen saturation (SpO2; 96.2±2.7 vs. 97.5±2.1%, p&lt;0.001) and amelioration of fever (&gt;37.8 for 6.6% on day 3,3.2% on day 5, and 0.6% on day 10), dyspnea (for 56.4% on day 5, 62.4% on day 7, and 81.2% on day 10), and cough (46.0% on day 5,73.0% on day 7, and 87.3% on day 10) were noted in an increasingly higher percentage of patients with continued therapy.Conclusion: The current study provides real-life data of favipiravir, which is a unique option in Turkey for treating COVID-19 patients.The results revealed that favipiravir is a well-tolerated agent with a low side-effect profile. However, it needs to be evaluated withwell-designed, dose-compared, randomized controlled studies for the evaluation of efficacy</p